Emery Pharma Citizen Petition

Control of Nitrosamine Impurities in Human Drugs

-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan. 21 https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press

Current Status of Angiotensin Receptor Blocker Recalls

II receptor blockers (ARBs) are widely prescribed. Since July 2018 >2 dozen safety-and-availability/fda-updates-and-press-announcements-angiotensin-.

NEW JERSEY DRUG UTILIZATION REVIEW BOARD

17 juil. 2019 (c) FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls. (Valsartan Losartan
durb agenda

FDA's Overview of the Guidance for Industry: Control of Nitrosamine

2 oct. 2020 FDA Updates and Press Announcements on Angiotensin II. Receptor Blocker (ARB) Recalls (Valsartan Losartan
SBIA Nitrosamine Webinar Oct

Recalls and alerts of poor quality sartans due to impurities in 2018

https://www.fda.gov/drugs/drug-safety-and-availability/fda- updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan (
inline supplementary material ?download=true

Emery Pharma Citizen Petition

2 janv. 2020 histamine receptor blocker (“H2 blocker”) that is extensively used ... -and-availability/fda-updates-and-press-announcements-ndma-zantac-.
EP Ranitidine FDA Citizen Petition v January

Ranitidine shortages following international recall: implications on

the FDA raising concerns that batches of ranitidine products FDA statement. FDA updates and press announcments on angiotensin II receptor blocker (ARB).
Ranitidine shortages following international recall implications on pre medication regimens to prevent hypersensitivity reactions for oncology treatments